High Prevalence of Stomach and Esophagus Problems Globally Creating Significant Scope for the Rabeprazole Sodium Market

During the forecast period, the global rabeprazole sodium market is expected to rise at a considerable CAGR. The market growth is being driven by the rising prevalence rate of gastroesophageal reflux diseases (GERD), duodenal ulcers, and other gut-related infections and diseases globally, which has surged the demand for better treatment options. As per the World Gastroenterology Organization, the prevalence rate of GERD is growing rapidly across the world. It was valued at approximately 2.5%-6.6% in South East Asia and almost 13.8%-25.8% in North America. Moreover, in 2019, the global prevalence of duodenal or peptic ulcer prevalence was approximately 8.09 million representing a 25.82% increase from 1990. The increase in the number of cigarette smokers, alcohol/tobacco consumers, and a significant increase in food habits are the major cause of these diseases. The prevalence of acid reflux and related symptoms has increased across the globe by nearly 50% over the last decade. This disorder not only has major effects on the health and quality of patient lives but also extends to the healthcare system and economy.

Browse the full report description of “Global Rabeprazole Sodium Market Size, Share and Trends Analysis Report, By Type (Rabeprazole Sodium Monohydrate and Rabeprazole Sodium Crystalline), By Application (Gastroesophageal Reflux Disease Treatment, Duodenal Ulcer Treatment, and Others), Forecast (2022-2028)” at https://www.omrglobal.com/industry-reports/rabeprazole-sodium-market

The prominent players in the market are focusing on acquisition and partnership collaboration with other market players to broaden their product offering in order to fulfill the growing market demand. For instance, in December 2021, Pfizer Inc. acquired Arena Pharmaceuticals, Inc along with its all the outstanding shares for $100 per share in an all-cash transaction for a total equity value of approximately $6.7 billion, via a definitive agreement. Through this acquisition, the company acquired Arena’s portfolio which includes diverse and promising development-stage therapeutic candidates in gastroenterology, including etrasimod, an oral, selective sphingosine 1-phosphate (S1P) receptor modulator currently in development for a range of immuno-inflammatory diseases including gastrointestinal and dermatological diseases.

 Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028

Segment Covered- 

• By Type
• By Application

Regions Covered-

• North America
• Europe
• Asia-Pacific
• Rest of the World

Competitive Landscape- including ASN Co., Intas Pharmaceutical Ltd., Pfizer Inc., Sandoz Inc. (Novartis International AG)), Teva Pharmaceutical Industries Ltd., and others.?

Key questions addressed by the report

• What is the market growth rate?
• That segment and region dominate the market in the base year?
• That segment and region will project the fastest growth in the market?
• How does COVID-19 impact the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Rabeprazole Sodium Market Report Segment

By Type

• Rabeprazole Sodium Monohydrate
• Rabeprazole Sodium Crystalline

By Application

• Gastroesophageal Reflux Disease Treatment
• Duodenal Ulcer Treatment
• Others

Global Rabeprazole Sodium Market Report Segment by Region

North America

• US
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe 

Asia-Pacific

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific 

Rest of the World

• Latin America 
• Middle East and Africa

To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/rabeprazole-sodium-market